Pordy, Robert

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 3,634

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 2,296

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 885

Evinacumab for Homozygous Familial Hypercholesterolemia

Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 793

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 572

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 470

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 408

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

Kereiakes, D. J., Robinson, J. G., Cannon, C. P., Lorenzato, C., Pordy, R., Chaudhari, U., & Colhoun, H. M. (2015) · American Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 349

ANGPTL3 inhibition in homozygous familial hypercholesterolemia

Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 323

Evinacumab in Patients with Refractory Hypercholesterolemia

Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 302

Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome

Jukema, J. W., Szarek, M., Zijlstra, L. E., de Silva, H. A., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 243

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Edelberg, J. M., Goodman, S. G., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 173

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies

Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 172

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Baum, S. J., Bergeron, J., Kershaw, E. E., Moriarty, P. M., Rubba, P., Whitcomb, D. C., Banerjee, P., et al. (2023) · Nature Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 140

Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 127

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity

Banerjee, P., Chan, K.-C., Tarabocchia, M., Benito-Vicente, A., Alves, A. C., Uribe, K. B., Bourbon, M., Skiba, P. J., Pordy, R., Gipe, D. A., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 97

Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study

Janik, M. J., Urbach, D. V., van Nieuwenhuizen, E., Zhao, J., Yellin, O., Baccara-Dinet, M. T., Pordy, R., & Manvelian, G. (2021) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 51

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White, H. D., Schwartz, G. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 41

GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial

Gonzalez Trotter, D., Donahue, S., Wynne, C., Ali, S., Parasoglou, P., Boyapati, A., Mohammadi, K., Musser, B. J., Meier, P., Mastaitis, J., et al. (2025) · Nature Communications

Muscle Physiology and DisordersTGF-β signaling in diseases

Cited by 23

Evinacumab: Mechanism of action, clinical, and translational science

Dingman, R., Bihorel, S., Gusarova, V., Mendell, J., & Pordy, R. (2024) · Clinical and Translational Science

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 23

Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials

Rosenson, R. S., Rader, D. J., Ali, S., Banerjee, P., McGinniss, J., & Pordy, R. (2025) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 13

Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial

Rosenson, R. S., George, R. T., Sanchez, R. J., Zhao, X.-Q., Ponda, M. P., Waldron, A., & Pordy, R. (2025) · Journal of Clinical Lipidology

Pancreatitis Pathology and TreatmentLipid metabolism and disorders

Cited by 11